Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
Carvajal RD, Lawrence DP, Weber JS, Gajewski TF, Gonzalez R, Lutzky J, O'Day SJ, Hamid O, Wolchok JD, Chapman PB, Sullivan RJ, Teitcher JB, Ramaiya N, Giobbie-Hurder A, Antonescu CR, Heinrich MC, Bastian BC, Corless CL, Fletcher JA, Hodi FS. Carvajal RD, et al. Among authors: hodi fs. Clin Cancer Res. 2015 May 15;21(10):2289-96. doi: 10.1158/1078-0432.CCR-14-1630. Epub 2015 Feb 18. Clin Cancer Res. 2015. PMID: 25695690 Free PMC article. Clinical Trial.
Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G. Soiffer R, et al. Among authors: hodi fs. J Clin Oncol. 2003 Sep 1;21(17):3343-50. doi: 10.1200/JCO.2003.07.005. J Clin Oncol. 2003. PMID: 12947071 Clinical Trial.
Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity.
Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG. Linette GP, et al. Among authors: hodi fs. Clin Cancer Res. 2005 Nov 1;11(21):7692-9. doi: 10.1158/1078-0432.CCR-05-1198. Clin Cancer Res. 2005. PMID: 16278389 Clinical Trial.
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG; Cancer and Leukemia Group B. Roberts JD, et al. Among authors: hodi fs. J Immunother. 2006 Jan-Feb;29(1):95-101. doi: 10.1097/01.cji.0000195295.74104.ad. J Immunother. 2006. PMID: 16365605 Clinical Trial.
Cytotoxic T-lymphocyte-associated antigen-4.
Hodi FS. Hodi FS. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5238-42. doi: 10.1158/1078-0432.CCR-07-0813. Clin Cancer Res. 2007. PMID: 17875750 Review.
Modeling genomic diversity and tumor dependency in malignant melanoma.
Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, Hodi FS, Dranoff G, Sellers WR, Thomas RK, Meyerson M, Golub TR, Dummer R, Herlyn M, Getz G, Garraway LA. Lin WM, et al. Among authors: hodi fs. Cancer Res. 2008 Feb 1;68(3):664-73. doi: 10.1158/0008-5472.CAN-07-2615. Cancer Res. 2008. PMID: 18245465 Free PMC article.
Major response to imatinib mesylate in KIT-mutated melanoma.
Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE. Hodi FS, et al. J Clin Oncol. 2008 Apr 20;26(12):2046-51. doi: 10.1200/JCO.2007.14.0707. J Clin Oncol. 2008. PMID: 18421059 No abstract available.
393 results